We conducted a phase I clinical trial of an experimental live attenuated recombinant human metapneumovirus (HMPV) vaccine (rHMPV-Pa) sequentially in adults, HMPV-seropositive children, and HMPV-seronegative children, the target population for vaccination. rHMPV-Pa was appropriately restricted in replication in adults and HMPV-seropositive children but wasoverattenuated for HMPV-seronegative children.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of the Pediatric Infectious Diseases Society|
|State||Published - Feb 19 2018|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Infectious Diseases